AnaptysBio has established multiple partnerships where our SHM-XEL™ platform has been utilized to generate novel antibodies for various purposes. AnaptysBio’s partners range from biotechnology and pharmaceutical companies to government agencies, as follows:
|
Partners
|
|
Partner
|
Goal/Target
|
Press Release
|
|
Merck
|
Develop novel antibody therapeutics to an undisclosed disease target
|
 |
|
VLST
|
Generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders
|
|
|
Roche
|
Generate novel antibodies for human therapy
|
|
|
Undisclosed Pharma
|
Generate novel antibodies to specified disease targets
|
|
|
DARPA
|
Improve thermo stability of antibodies for the use in military biosensors
|
|
|
Novartis
|
Discovery and maturation to multiple disease targets
|
|
|
For more information please contact
Corporate Development, at
corpdev@anaptysbio.com
